Axsome Therapeutics, Inc. NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Several other equities research analysts have also issued reports on AXSM. Leerink Partners lifted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company ...

View Our Latest Stock Analysis on AXSM Axsome Therapeutics Stock Up 0.1 % AXSM opened at $131.68 on Thursday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ...

The key criteria for those in the top-tier positions appear to be loyalty, wealth, and ideological fervor, not competence.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

Tom Sietsema has been The Washington Post's food critic since 2000. In leaner years, he worked for the Microsoft Corp., where he launched sidewalk.com; the Seattle Post-Intelligencer; the San ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Highlights,Financial institutions have adjusted their outlook on Axsome Therapeutics, revising expectations.,Institutional investors hold a significant portion of the company’s shares, reflecting ...